Somatoform Symptoms in Parkinson Disease

Area of Science:

• Neurology
• Psychiatry
• Geriatrics

Background:

• Parkinson disease (PD) diagnosis and treatment are complicated by co-occurring somatoform symptoms.
• Understanding the interplay between somatoform symptoms and PD is crucial for effective patient management.

Purpose of the Study:

• To investigate the relationship between somatoform symptom severity and Parkinson disease.
• To compare demographic and clinical features across PD patient subgroups with varying levels of somatoform symptoms.

Main Methods:

• 1093 individuals with PD were categorized into four subgroups based on somatoform symptom severity using the Brief Symptom Inventory-18 (BSI-18).
• Demographic data and disease severity measures, including the Unified Parkinson's Disease Rating Scale and SF-12 Health Status Survey, were used for subgroup assessment.

Main Results:

• 56% of individuals with PD exhibited high or very high somatoform symptom levels.
• Increased somatoform symptoms were significantly associated with female gender, lower socioeconomic status, longer disease duration, greater PD severity and disability, higher depression and anxiety scores, lower cognitive function, reduced self-efficacy, poorer quality of life, and increased medical comorbidity.
• No significant differences were observed in age, race, or marital status between subgroups.

Conclusions:

• Somatoform symptom severity in Parkinson disease is linked to increased disease severity and disability.
• Females and individuals with lower socioeconomic status are more likely to experience higher levels of somatoform symptoms in PD.
• Enhanced awareness and management of somatoform symptoms can potentially improve overall treatment outcomes for Parkinson disease patients.